Related Experiment Video
Updated: May 6, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Update on tolterodine extended-release for treatment of overactive bladder
Tola Omotosho1, Chi Chiung Grace Chen
1Women's Center for Pelvic Health, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract:
Overactive bladder is a prevalent condition which negatively impacts quality of life and puts a significant economical burden on society. First-line therapy often includes pharmacotherapy with antimuscarinic medications, and numerous research studies have demonstrated that tolterodine extended-release (ER) is an efficacious and tolerable formulation of this class of medication. This review provides an update on the clinical use of tolterodine ER, detailing the current literature on its efficacy, tolerability, adverse effects, and comparability with other commonly prescribed medications for the treatment of overactive bladder.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Modified-Release Drug Delivery Systems: Overview
Urinary Tract Calculi III: Medical Management
Oral Drug Delivery Systems: Continuous-Release Systems
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Drugs for Treatment of Constipation-Predominant IBS

